Biomerica's inFoods IBS Shows Nearly 50 Percent Symptom Relief in Real-World Data

Biomerica Inc. (BMRA) has released real-world findings showing that its inFoods IBS therapy significantly reduced symptoms in patients suffering from irritable bowel syndrome (IBS). Based on data from over 360 patients, participants reported an average 48.5 percent drop in gastrointestinal pain and a 49.8 percent reduction in bloating after an eight-week treatment period.

The inFoods IBS approach uses a diagnostic blood test to pinpoint individual food triggers that worsen IBS symptoms. Patients then follow a personalized elimination diet to avoid these foods, rather than relying on broad restrictions or medications. The results from this real-world study support and in some cases outperform outcomes seen in earlier clinical trials.

Biomerica also announced the launch of a new real-time feedback platform that allows physicians to monitor patient-reported outcomes throughout the course of therapy. This tool gives clinicians insight into changes in pain, bloating and overall wellness, enabling more responsive and individualized treatment plans.

IBS is a chronic digestive condition that affects roughly 10 to 15 percent of adults in the United States. Traditional treatment typically involves medications that can have side effects, or generalized diets that may not work for everyone. inFoods IBS offers a non-drug, precision-based approach that targets the root cause of symptoms by identifying specific food reactions unique to each patient.

Earlier peer-reviewed research from institutions including the Cleveland Clinic and the University of Michigan found that patients using inFoods dietary guidance experienced significantly more relief from abdominal pain than those following a placebo diet. That study showed a 59.6 percent pain responder rate in the treatment group compared to 42.1 percent in the placebo group.

Biomerica's new data builds on these findings by showing consistent benefits in a broader, real-world setting. The therapy is currently being used in clinics across the country, where patients begin with a simple finger-stick blood test. Based on the results, doctors create a personalized food plan aimed at reducing symptoms like bloating, constipation and diarrhea without the use of pharmaceuticals.

As IBS continues to be a leading cause of gastrointestinal discomfort and lost productivity, Biomerica believes its diagnostic-guided approach offers an accessible and cost-effective solution. The inFoods system allows both patients and providers to move away from guesswork and toward targeted dietary changes with measurable results.

The post Biomerica's inFoods IBS Shows Nearly 50 Percent Symptom Relief in Real-World Data appeared first on PRISM MarketView.

COMTEX_465710036/2927/2025-05-22T14:31:08